Cat. No.: HY-N0442

5-O-Methylvisammioside

(Synonyms: 4'-O-β-D-Glucosyl-5-O-methylvisamminol)

고객리뷰

Based on 1 Customer Validation

5-O-Methylvisammioside (4'-O-β-D-Glucosyl-5-O-methylvisamminol) is an orally active natural chromone glycoside and multiple biological activities. 5-O-Methylvisammioside inhibits ferroptosis by activating the Nrf2/HO-1 signaling axis. 5-O-Methylvisammioside alleviates intestinal barrier damage by inhibiting the ROS/NF-κB/NLRP3 pathway. 5-O-Methylvisammioside exerts a protective effect against acute liver injury by reducing ALT/AST, decreasing inflammatory infiltration, and inhibiting IκB-α phosphorylation and NF-κB nuclear translocation. 5-O-Methylvisammioside blocks the HMGB1/RAGE/MEK/ERK signaling axis to exert anti-tumor and anti-angiogenic effects. 5-O-Methylvisammioside improves depression-like behaviors by inhibiting Src kinase and the NF-κB pathway.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.90%
CAS No.: 84272-85-5
화학식: C₂₂H₂₈O₁₀
분자량:452.45

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

5-O-Methylvisammioside Chemical Structure

CAS No.: 84272-85-5

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- In Vitro
- In Vivo
Chemical Information
용액&용해도
- In Vitro
- In Vivo
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

All NF-κB Isoforms :

All p38 MAPK Isoforms :

All JNK Isoforms :

All Src Isoforms :

All TNF Receptor Isoforms :

All NOD-like Receptor (NLR) Isoforms :

All MEK Isoforms :

All ERK Isoforms :

All VEGFR Isoforms :

In Vitro

5-O-Methylvisammioside effectively blocks the production of inflammatory cytokines induced by lipopolysaccharide in BV-2 microglial cells^[1].
5-O-Methylvisammioside (50-500 μg/mL; 24 h) shows no toxicity to human umbilical vein endothelial cells at concentrations up to 500 μg/mL, and inhibits HMGB1-induced proliferation of human umbilical vein endothelial cells in a dose-dependent manner^[2].
5-O-Methylvisammioside (100-500 μg/mL; 24 h) dose-dependently inhibits HMGB1-induced migration of human umbilical vein endothelial cells in wound healing assays^[2].
5-O-Methylvisammioside (100-500 μg/mL; 24 h) dose-dependently inhibits HMGB1-induced migration of human umbilical vein endothelial cells in Transwell assays^[2].
5-O-Methylvisammioside (100-500 μg/mL; 16 h) dose-dependently inhibits HMGB1-induced tube formation in human umbilical vein endothelial cells^[2].
5-O-Methylvisammioside (100-500 μg/mL) dose-dependently inhibits HMGB1-induced upregulation of RAGE, phosphorylated MEK, and phosphorylated ERK in human umbilical vein endothelial cells^[2].
5-O-Methylvisammioside (250 μg/mL) inhibits HMGB1-induced upregulation of RAGE in human umbilical vein endothelial cells^[2].
5-O-Methylvisammioside (100-500 μg/mL) dose-dependently inhibits HMGB1-induced VEGF production in human umbilical vein endothelial cells^[2].
5-O-Methylvisammioside (40 μM; 48 h) significantly reduces oxidative stress levels, corrects iron metabolism disorders, restores the expression levels of ferroptosis-related proteins, and decreases proinflammatory cytokine levels in Erastin (HY-15763)-treated Caco-2 cells. These protective effects strictly depend on the Nrf2/HO-1 pathway, as Nrf2 knockdown significantly attenuates the aforementioned effects^[3].
5-O-Methylvisammioside (10 μM; 45 min) potently inhibits CNT2-mediated adenosine uptake in HEK293 cells overexpressing CNT2, with an IC₅₀ of 11.22 μM, and exhibits stronger activity than other tested compounds at the concentration of 10 μM^[4].
5-O-Methylvisammioside (10 μM; 24 h) inhibits ROS production in human intestinal epithelial cells stimulated with 720 μM uric acid (UA) (HY-B2130) for 24 h, which is confirmed by reduced DCFH-DA fluorescence intensity and regulated mRNA expression of SOD/NOX4^[4].
5-O-Methylvisammioside (10 μM; 24 h) inhibits the activation of the ROS/NF-κB/NLRP3 pathway and restores the expression of tight junction proteins in human intestinal epithelial cells stimulated with 720 μM UA for 24 h^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay^[2]

Cell Line:

human umbilical vein endothelial cells (HUVECs)
Concentration:

100, 250, 500 μg/mL
Incubation Time:

24 h
Result:

Dose-dependently reduced HMGB1-enhanced wound closure at 100, 250, 500 μg/mL, with significant inhibition observed at all tested concentrations.\n
Significantly reduced the number of HMGB1-increased migrated cells at 100, 250, 500 μg/mL, with dose-dependent inhibition observed.

Western Blot Analysis^[4]

Cell Line:

UA-stimulated human intestinal epithelial cells (HIEC)
Concentration:

10 μM
Incubation Time:

24 h
Result:

Significantly reduced phosphorylation of NF-κB p65, and decreased protein expression of NLRP3, ASC, and caspase-1 in UA-stimulated HIEC.
Increased protein expression of tight junction proteins ZO-1 and Occludin in UA-stimulated HIEC.

In Vivo

5-O-methylvisammioside (5-10 mg/kg; i.p.; once daily; 7 days) ameliorates Acetaminophen (HY-66005)-induced acute liver injury in male ICR mice by inhibiting the TNF, MAPK, NF-κB, and arachidonic acid pathways, reducing serum liver enzyme and inflammatory cytokine levels, and improving liver histopathology^[1].
5-O-Methylvisammioside (12.5-50 mg/kg; once daily; 14 days) dose-dependently inhibits orthotopic hepatocellular carcinoma growth in C57BL/6 mice, with a maximum tumor inhibition rate of 62.64% at 50 mg/kg, by suppressing tumor angiogenesis and downregulating the HMGB1/RAGE/MEK/ERK signaling pathway^[2].
5-O-Methylvisammioside (3.5-7 mg/kg/day; i.p.; once daily; 14 days) dose-dependently alleviates DSS (HY-116282C)-induced ulcerative colitis in male Sprague-Dawley rats^[3].
5-O-Methylvisammioside (5-20 mg/kg; i.g.; single dose) reduces peak serum uric acid levels in single-dose HUA mice by up to 39.1% (10 mg/kg dose) and accelerates the return to baseline uric acid levels^[4].
5-O-Methylvisammioside (5-20 mg/kg; i.g.; once daily; 4 weeks) reduces serum uric acid and adenosine levels, improves liver/kidney function, alleviates intestinal inflammation and oxidative stress, restores intestinal barrier function, and normalizes intestinal CNT2 expression in chronic HUA mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

ICR (male, adult, 20-22 g, acetaminophen-induced acute liver injury)^[1]
Dosage:

5 mg/kg; 10 mg/kg
Administration:

i.p.; daily; 7 days
Result:

Significantly reduced serum alanine aminotransferase and aspartate aminotransferase levels compared to the acetaminophen-only group.
Significantly reduced liver inflammatory cell infiltration and hepatocyte vacuolation compared to the acetaminophen-only group.
Significantly decreased serum TNF-α and IL-1β levels compared to the acetaminophen-only group.
Significantly suppressed hepatic mRNA expression of TNF-α, IL-1β, Ptges, p38, and RelB compared to the acetaminophen-only group.
Significantly inhibited IκB-α phosphorylation and NF-κB nuclear translocation compared to the acetaminophen-only group.
Significantly suppressed phosphorylation of JNK and p38 in the MAPK pathway compared to the acetaminophen-only group, with no significant effect on Erk1/2 phosphorylation.
Regulated 4675 differentially expressed hepatic genes compared to the acetaminophen-only group, with enrichment in TNF, MAPK, NF-κB, and arachidonic acid pathways at 10 mg/kg dose.
Regulated 249 hepatic metabolites compared to the acetaminophen-only group, including significant reduction in pro-inflammatory prostaglandins (D2, B2, A2) linked to the arachidonic acid pathway at 10 mg/kg dose.

Animal Model:

C57BL/6 (male, 8 weeks old, 20g)^[2]
Dosage:

12.5 mg/kg; 25 mg/kg; 50 mg/kg
Administration:

daily; 14 days
Result:

Reduced tumor weight with tumor inhibition rates of 42.24%, 55.48%, and 62.64% for the 12.5 mg/kg, 25 mg/kg, and 50 mg/kg doses, respectively.
Decreased CD31 H-scores in tumor tissues across all three doses.
Exhibited dose-dependent reductions in HMGB1, RAGE, p-MEK, and p-ERK protein levels compared to the model group.
Reduced tumor tissue HMGB1 levels and VEGF levels across all three doses.
Caused no significant changes in body weight during the 14-day period.

Animal Model:

Sprague-Dawley (male, 6 weeks old, 200 g, specific pathogen-free, ulcerative colitis induced by 3% dextran sulfate sodium)^[3]
Dosage:

3.5 mg/kg/day; 7 mg/kg/day
Administration:

i.p.; daily; 14 days
Result:

Reduced disease activity index scores compared to the DSS model group, with the high dose showing greater efficacy.
Significantly increased colon length, reduced colon damage index scores, lowered spleen index, and increased thymus index.
Partially ameliorated mucosal ulceration, crypt atrophy, and inflammatory infiltration at low dose; showed improved gland/crypt organization and reduced inflammation, with near-normal mucosa similar to mesalazine at high dose.
Reduced colon tissue levels of IL-6, IL-8, and TNF-α.
Restored goblet cell numbers, upregulated protein and mRNA levels of tight junction proteins occludin and ZO-1.
Reduced oxidative stress markers MDA, 4-HNE, and MPO activity, and increased GSH content.
Reduced total iron content, upregulated FTH1 expression, and downregulated Tfrc and Slc11a2 levels to restore iron homeostasis.
Improved mitochondrial morphology (reduced swelling, increased cristae organization) compared to the DSS group, with high-dose rats showing discernible mitochondrial double membranes.
Upregulated protein and mRNA levels of ferroptosis markers GPX4 and SLC7A11, and downregulated ACSL4.
Dose-dependently upregulated protein and mRNA levels of Nrf2 and HO-1, with high-dose levels exceeding normal control levels.

Animal Model:

C57BL/6J (6-week-old, SPF-grade, male, hyperuricemia induced by daily intraperitoneal injection of potassium oxonate plus intragastric gavage of yeast paste for single-dose study)^[4]
Dosage:

5 mg/kg; 10 mg/kg; 20 mg/kg
Administration:

i.g.; single dose
Result:

Reduced peak serum uric acid levels to 194.44 μM (5 mg/kg), 174.76 μM (10 mg/kg), 176.93 μM (20 mg/kg).
Lowered peak serum uric acid levels by up to 39.1% (10 mg/kg dose).
Accelerated serum uric acid return to pre-dose levels by 4 h post-treatment.

Animal Model:

C57BL/6J (6-week-old, SPF-grade, male, hyperuricemia induced by daily intraperitoneal injection of potassium oxonate plus intragastric gavage of yeast paste for 4 weeks)^[4]
Dosage:

5 mg/kg; 10 mg/kg; 20 mg/kg
Administration:

i.g.; daily; 4 weeks
Result:

Significantly reduced serum uric acid levels in all treated groups, with the 10 mg/kg dose showing the greatest reduction.
Significantly decreased serum and urine adenosine levels; 5 and 10 mg/kg doses showed better inhibitory effects on adenosine absorption than positive control drugs.
Significantly reduced elevated CNT2 protein expression in the duodenum, jejunum, and ileum induced by HUA.
Ameliorated liver pathology (bile duct hyperplasia, inflammatory cell infiltration, steatosis) and kidney pathology (renal tubular epithelial cell edema, tubular/corpuscle dilation, inflammatory cell infiltration), and reduced serum ALT, AST, and Cr levels compared to the model group.
Significantly decreased serum and intestinal levels of inflammatory factors (IL-1β, IL-6, TNF-α) and oxidative stress marker MDA, while increased serum SOD levels compared to the model group.
Reduced intestinal permeability (measured via FITC-dextran), and restored intestinal tight junction protein expression (ZO-1, Occludin) in the duodenum, jejunum, and ileum compared to the model group.
Improved intestinal histopathology (epithelial detachment, shortened/sparse villi, inflammatory cell infiltration) and preserved villi structure.

Chemical Information

CAS No. 84272-85-5
Appearance Solid
분자량 452.45
화학식 C₂₂H₂₈O₁₀
Color White to off-white
SMILES

O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](OC(C)([C@H]2OC3=C(C(OC)=C(C(C=C(C)O4)=O)C4=C3)C2)C)[C@@H]1O
Synonyms

4'-O-β-D-Glucosyl-5-O-methylvisamminol
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
- Plants
- Umbelliferae
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

용액&용해도

In Vitro:

DMSO : 50 mg/mL (110.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 25 mg/mL (55.25 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2102 mL

11.0509 mL

22.1019 mL

5 mM

0.4420 mL

2.2102 mL

4.4204 mL

10 mM

0.2210 mL

1.1051 mL

2.2102 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (292 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhang T, et al. Multi-omics reveals that 5-O-methylvisammioside prevention acute liver injury in mice by regulating the TNF/MAPK/NF-κB/arachidonic acid pathway. Phytomedicine. 2024 Jun;128:155550.
[Content Brief]

[2]. Hou W, et al. 5-O-Methylvisammioside inhibits HMGB1-induced Angiogenesis of hepatocellular carcinoma through RAGE/MEK/ERK signaling pathway. PLoS One. 2025;20(5):e0322056. Published 2025 May 5. [Content Brief]

[3]. Li D, et al. Nrf2/HO-1-dependent inhibition of ferroptosis underlies the antioxidant effects of 5-O-methylvisammioside in colitis. Front Immunol. 2026;16:1738408. Published 2026 Jan 20. [Content Brief]

[4]. Mai S, et al. 5-O-Methylvisammioside, a novel inhibitor of CNT2, improves hyperuricemia by inhibiting intestinal purine nucleoside absorption with a safe profile. Biochem Pharmacol. Published online August 13, 2025. [Content Brief]

[5]. Zhu W, et al. 5-O-Methylvisammioside alleviates depression-like behaviors by inhibiting nuclear factor kappa B pathway activation via targeting SRC. Neural Regeneration Research. 2026 Aug 1;21(8):3659-67.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	2.2102 mL	11.0509 mL	22.1019 mL	55.2547 mL
	5 mM	0.4420 mL	2.2102 mL	4.4204 mL	11.0509 mL
	10 mM	0.2210 mL	1.1051 mL	2.2102 mL	5.5255 mL
	15 mM	0.1473 mL	0.7367 mL	1.4735 mL	3.6836 mL
	20 mM	0.1105 mL	0.5525 mL	1.1051 mL	2.7627 mL
	25 mM	0.0884 mL	0.4420 mL	0.8841 mL	2.2102 mL
	30 mM	0.0737 mL	0.3684 mL	0.7367 mL	1.8418 mL
	40 mM	0.0553 mL	0.2763 mL	0.5525 mL	1.3814 mL
	50 mM	0.0442 mL	0.2210 mL	0.4420 mL	1.1051 mL
DMSO	60 mM	0.0368 mL	0.1842 mL	0.3684 mL	0.9209 mL
	80 mM	0.0276 mL	0.1381 mL	0.2763 mL	0.6907 mL
	100 mM	0.0221 mL	0.1105 mL	0.2210 mL	0.5525 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

5-O-Methylvisammioside

Bioactive Compound Library Max

Bioactive Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Inflammasomes related Compound Library

Multi-Target Compound Library

Radioprotector Library

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Tibetan Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Pattern Recognition Receptors Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library